Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML 17 treatment development in younger AML and high-risk MDS
2007-003798-16Phase 2Unknown
- Sponsor
- Cardiff University
- Start
- Aug 2007
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of gemtuzumab ozogamicin and pacritinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Cardiff University. Primary endpoint: Complete remission achievement. Status: unknown.
02
Drugs
gemtuzumab ozogamicinpacritinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2007-003798-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003798-16.